These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29074404)

  • 1. Are rodent models of Parkinson's disease behaving as they should?
    Vingill S; Connor-Robson N; Wade-Martins R
    Behav Brain Res; 2018 Oct; 352():133-141. PubMed ID: 29074404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Historical Perspective: Models of Parkinson's Disease.
    Chia SJ; Tan EK; Chao YX
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32252301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rodent models of impulsive-compulsive behaviors in Parkinson's disease: How far have we reached?
    Cenci MA; Francardo V; O'Sullivan SS; Lindgren HS
    Neurobiol Dis; 2015 Oct; 82():561-573. PubMed ID: 26325219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Back and to the Future: From Neurotoxin-Induced to Human Parkinson's Disease Models.
    Airavaara M; Parkkinen I; Konovalova J; Albert K; Chmielarz P; Domanskyi A
    Curr Protoc Neurosci; 2020 Mar; 91(1):e88. PubMed ID: 32049438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling Parkinson's disease and treatment complications in rodents: Potentials and pitfalls of the current options.
    Francardo V
    Behav Brain Res; 2018 Oct; 352():142-150. PubMed ID: 29237549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
    Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
    Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Atypical' Parkinson's disease - genetic.
    Weissbach A; Wittke C; Kasten M; Klein C
    Int Rev Neurobiol; 2019; 149():207-235. PubMed ID: 31779813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autosomal dominant Parkinson's disease: Incidence of mutations in LRRK2, SNCA, VPS35 and GBA genes in Brazil.
    Abreu GM; Valença DC; Campos M; da Silva CP; Pereira JS; Araujo Leite MA; Rosso AL; Nicaretta DH; Vasconcellos LF; da Silva DJ; Della Coletta MV; Dos Santos JM; Gonçalves AP; Santos-Rebouças CB; Pimentel MM
    Neurosci Lett; 2016 Dec; 635():67-70. PubMed ID: 27777137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Developments in Genetic rat models of Parkinson's Disease.
    Creed RB; Goldberg MS
    Mov Disord; 2018 May; 33(5):717-729. PubMed ID: 29418019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Animal models for Parkinson's disease.
    Ikuno M; Takahashi R
    Nihon Rinsho; 2017 Jan; 75(1):42-46. PubMed ID: 30566293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetics of Parkinson's disease--state of the art, 2013.
    Bonifati V
    Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S23-8. PubMed ID: 24262182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of LRRK2, SNCA, Parkin, PINK1, and DJ-1 in Zambian patients with Parkinson's disease.
    Yonova-Doing E; Atadzhanov M; Quadri M; Kelly P; Shawa N; Musonda ST; Simons EJ; Breedveld GJ; Oostra BA; Bonifati V
    Parkinsonism Relat Disord; 2012 Jun; 18(5):567-71. PubMed ID: 22445250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resequencing analysis of five Mendelian genes and the top genes from genome-wide association studies in Parkinson's Disease.
    Benitez BA; Davis AA; Jin SC; Ibanez L; Ortega-Cubero S; Pastor P; Choi J; Cooper B; Perlmutter JS; Cruchaga C
    Mol Neurodegener; 2016 Apr; 11():29. PubMed ID: 27094865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Classic and new animal models of Parkinson's disease.
    Blesa J; Phani S; Jackson-Lewis V; Przedborski S
    J Biomed Biotechnol; 2012; 2012():845618. PubMed ID: 22536024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study.
    Simuni T; Uribe L; Cho HR; Caspell-Garcia C; Coffey CS; Siderowf A; Trojanowski JQ; Shaw LM; Seibyl J; Singleton A; Toga AW; Galasko D; Foroud T; Tosun D; Poston K; Weintraub D; Mollenhauer B; Tanner CM; Kieburtz K; Chahine LM; Reimer A; Hutten SJ; Bressman S; Marek K;
    Lancet Neurol; 2020 Jan; 19(1):71-80. PubMed ID: 31678032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the genetic variability in Parkinson's disease from Southern Spain.
    Bandrés-Ciga S; Mencacci NE; Durán R; Barrero FJ; Escamilla-Sevilla F; Morgan S; Hehir J; Vives F; Hardy J; Pittman AM
    Neurobiol Aging; 2016 Jan; 37():210.e1-210.e5. PubMed ID: 26518746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions.
    Johnson ME; Bobrovskaya L
    Neurotoxicology; 2015 Jan; 46():101-16. PubMed ID: 25514659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive and psychiatric symptoms in genetically determined Parkinson's disease: a systematic review.
    Piredda R; Desmarais P; Masellis M; Gasca-Salas C
    Eur J Neurol; 2020 Feb; 27(2):229-234. PubMed ID: 31686421
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.